Pure Global
NCT06225297

Evaluation of a Package of Interventions to Reduce the Burden of Malaria in the Urban Daaras of Touba, Senegal

Evaluation of Vector and Chemoprevention-based Interventions to Reduce Malaria Burden in Urban Daaras of Touba, Senegal
PATH·Phase 4·ClinicalTrials.gov·combination productNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Malaria
Drug/Device/Intervention
Intervention package
Study type
Interventional
Intervention type
combination product
Sponsor & location
Primary sponsor
PATH
Timeline & enrollment
Phase
Phase 4
Start date
Jan 01, 2024
End date
Feb 01, 2025
Enrollment
4600 participants
Primary outcome

Difference in cumulative incidence of clinical malaria confirmed by rapid diagnostic test (RDT) between arms,Difference in pre-post change in prevalence of microscopy-confirmed infection between arms,Difference in pre-post change in prevalence of PCR-confirmed infection between arms

Summary

This study aims to evaluate the effectiveness of the use of adapted insecticide-treated
 mosquito nets combined with extended DHA-PQ-based seasonal chemoprevention for all ages and
 behavior change communication in reducing the burden of malaria in relation to standards of
 protection and care among students (taalibés) in the daaras (Koranic schools) of Touba,
 Senegal.

ICD-10 classifications
Unspecified malariaPlasmodium malariae malariaPlasmodium falciparum malariaOther parasitologically confirmed malariaPlasmodium ovale malaria
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06225297
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06225297 through Pure Global AI's free database. This Phase 4 trial is sponsored by PATH and is currently Not yet recruiting. The study focuses on Malaria. Target enrollment is 4600 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.